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ABSTRACT
Glioblastoma is the most malignant brain tumor, exhibiting remarkable 
resistance to treatment. Here we investigated the oncogenic potential of HOXA9 
in gliomagenesis, the molecular and cellular mechanisms by which HOXA9 renders 
glioblastoma more aggressive, and how HOXA9 affects response to chemotherapy and 
survival. The prognostic value of HOXA9 in glioblastoma patients was validated in two 
large datasets from TCGA and Rembrandt, where high HOXA9 levels were associated 
with shorter survival. Transcriptomic analyses identified novel HOXA9-target genes 
with key roles in cancer-related processes, including cell proliferation, DNA repair, 
and stem cell maintenance. Functional studies with HOXA9-overexpressing and 
HOXA9-silenced glioblastoma cell models revealed that HOXA9 promotes cell viability, 
stemness and invasion, and inhibits apoptosis. Additionally, HOXA9 promoted the 
malignant transformation of human immortalized astrocytes in an orthotopic in vivo 
model, and caused tumor-associated death. HOXA9 also mediated resistance to 
temozolomide treatment in vitro and in vivo via upregulation of BCL2. Importantly, 
the pharmacological inhibition of BCL2 with the BH3 mimetic ABT-737 reverted 
temozolomide resistance in HOXA9-positive cells. These data establish HOXA9 as a 
driver of glioma initiation, aggressiveness and resistance to therapy. In the future, 
the combination of BH3 mimetics with temozolomide should be further explored as 
an alternative treatment for glioblastoma.
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INTRODUCTION
Glioblastoma (GBM) is the most common and 
malignant glioma type of the central nervous system [1]. 
Annually ~10,000 new cases are diagnosed in the United 
States, and > 50,000 patients live with the disease [2]. 
The clinical evolution is poor and variable among patients 
[3], and ~32% of all diagnosed cases survive less than 1 
year [2]. A pivotal phase III clinical trial in 2005 showed 
that temozolomide-based chemotherapy plus radiation 
was significantly more effective than radiation alone [4]. 
A more recent study validated the therapeutic benefit of 
radiotherapy with concomitant and adjuvant temozolomide 
as compared to radiotherapy alone [5]. The methylation 
status of the promoter region of MGMT is one of the most 
promising prognostic biomarkers of GBM: a methylated 
MGMT promoter is associated with a more effective tumor 
response to temozolomide and increased survival of GBM 
patients [6]. Mechanistically, MGMT methylation reduces 
gene expression, which decreases tumor cells’ ability 
to repair temozolomide-induced DNA damages, thus 
increasing drug sensitivity [6]. However, this association 
is not universal, as some tumors with a methylated MGMT 
promoter do not benefit from temozolomide treatment, 
while others with unmethylated MGMT respond favorably 
[7]. Therefore, there is an emerging need in discovering 
new molecular markers of drug response.
An aberrant expression of many of the 39 HOX 
genes has been found in various human cancers, 
affecting several hallmarks of cancer, including increased 
proliferation, angiogenesis, invasion, and resistance to 
apoptosis [8–11]. In gliomas, several HOX genes were 
shown to be part of large gene expression signatures 
that are associated with the maintenance of GBM stem 
cells and therapy resistance [12–15]. Specifically, it was 
shown that HOXA9 and HOXA10 have prognostic value 
in adult and pediatric high-grade glioma patients [12, 13, 
16]. While HOXA10 was recently shown to drive the 
expression of genes with critical roles in gliomagenesis 
[14] and to increase temozolomide resistance in vitro 
[15], the downstream mechanisms by which HOXA9 
may contribute to poor outcomes in GBM patients have 
not been addressed. Given its prognostic value, a more 
complete understanding of the molecular targets and 
the functional consequences of HOXA9 activation on 
the establishment and maintenance of the malignant 
phenotype of glioblastoma is required.
In this report, we pinpoint the genome-wide 
transcriptome of HOXA9 in GBM and demonstrate its 
functional relevance in initiating gliomas in vivo using 
immortalized astrocytes and established GBM cells. We 
also present data showing that HOXA9 promotes several 
oncogenic features, including increased cell viability, 
invasion, and stem cell-like features, and decreased 
sensitivity to temozolomide treatment in vitro and in 
vivo, and identify BCL2 as a putative therapeutic target 
to improve the response of HOXA9-positive GBMs 
to temozolomide. Our findings provide new insights 
regarding strategies to target HOXA9 overexpression in 
this incurable cancer.
RESULTS
HOXA9 is overexpressed and has prognostic 
value in GBM patients
HOXA9 expression was analyzed in WHO grades 
II/III glioma patients (27) and grade IV GBM patients 
(572) deposited in TCGA [17]. HOXA9 was found to 
be highly overexpressed in a subset of GBM patients 
comparing to lower grades glioma (LGG, WHO grades II/
III) patients and normal controls (Figure 1A), confirming 
that HOXA9 is associated with glioma grade and may be 
important in tumor progression. According to the four 
GBM molecular subgroups [18], HOXA9 overexpression 
was more frequent in the mesenchymal (10.34%) and in 
the proneural subtypes (7.02%; Figure 1B).
In order to explore putative mechanisms responsible 
for HOXA9 overexpression in GBM, HOXA9 copy 
number aberrations and DNA methylation levels were 
evaluated using the TCGA database (Figure 1C and 1D). 
HOXA9 was found to be amplified in 31% (114/372) of 
GBM patients (Figure 1C), of which only 7.9% (9/114) 
presented high levels of HOXA9 mRNA (p = 0.548, 
Chi-square test). Similarly, in the 25 methylation probes 
encompassing the HOXA9 locus that were evaluated, 
most presented a consistent methylation pattern across all 
patients (Figure 1D). Together, these results suggest that 
gene amplification or methylation are not major drivers of 
HOXA9 overexpression in glioma.
We have recently associated high levels of HOXA9 
expression with shorter overall survival (OS) of patients 
with GBM [16]. In order to validate this finding in a 
significantly larger and independent dataset, the prognostic 
value of HOXA9 was evaluated in 554 GBM patients with 
available survival data from TCGA [17]. Patients whose 
tumors present high HOXA9 expression had significantly 
shorter OS (median OS 323 days; 95% CI 183–463 days) 
than patients whose tumors express low HOXA9 levels 
(median OS 430 days; 95% CI 396–464 days; Log-
rank test p-value = 0.017; Figure 1E). Importantly, this 
association between HOXA9 and OS was independent 
of other putative prognostic variables, including patient 
age, gender, Karnofsky performance status, MGMT 
methylation and treatment with chemotherapy, as indicated 
by multivariate analysis (Cox model p-value = 0.017; 
Figure 1F). Interestingly, in GBM patients presenting 
low levels of MGMT expression, HOXA9 overexpression 
alone was sufficient to identify a subset of patients 
with shorter OS (median OS of 291 ± 75.4 and 435 ± 
19.2 days in HOXA9-positive versus HOXA9-negative 
patients, respectively; Log-rank, p-value = 0.013). The 
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Figure 1: HOXA9 expression is associated with WHO glioma grade and is an independent prognostic factor in 
glioblastoma patients. (A) Expression levels of HOXA9 in 10 unmatched normal controls, 27 lower-grade gliomas (LGG) and 572 
glioblastoma (GBM) patients from TCGA. HOXA9 is significantly overexpressed in GBM patients compared to LGG or normal samples 
(*** = p < 0.0001). (B) HOXA9 high expression (TCGA level 3 ≥ 3) is more frequent in the mesenchymal (10.34%) and in the proneural 
subtypes (7.02%). (C) HOXA9 gene copy number status in 372 GBM specimens from TCGA. HOXA9 is amplified (Log2 Copy Number 
Tumor/Normal ≥ 0.5) in 31% (n = 114) of GBM samples. The normal copy number interval is between the red dashed lines. (D) Heatmap 
representation of DNA methylation levels (TCGA β-values) of the chromosomal region encompassing HOXA9 in 74 GBM samples from 
TCGA. A total of 25 methylation probes (blue squares) were assessed, encompassing the CpG island (> 300 bp, represented in green). 
The color code (grades of red color corresponding to different methylation indexes) is shown below the heatmap. Each line corresponds 
to a patient and each column to a probe. The lines within HOXA9 correspond to introns. (E) Kaplan-Meier survival curves of 554 GBM 
patients from TCGA indicate that patients whose tumors present high levels of HOXA9 expression show a statistically significant shorter 
overall survival when compared to those whose tumors present lower levels of HOXA9 (Log-rank test, p-value = 0.017). (F) Univariate 
and multivariate analyses of associations between HOXA9 expression levels and survival of patients with glioblastoma (adjusted for patient 
age, KPS, gender, treatment with chemotherapy, and MGMT methylation status). (G) Kaplan-Meier survival curves of 181 GBM patients 
from REMBRANDT dataset confirms that patients whose tumors present high levels of HOXA9 expression (78/181) present a statistically 
significant shorter overall survival when compared to those whose tumors present lower levels (Log-rank test, p-value = 0.014).
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prognostic value of HOXA9 was additionally validated in 
an independent dataset from the REMBRANDT database 
(Log-rank, p-value = 0.014; Figure 1G).
Together, these data implicate HOXA9 as a critical 
molecule in the malignant progression of gliomas, and 
validate its prognostic value in high-grade GBM patients.
HOXA9-mediated transcriptomic signatures in 
GBM sustain cancer-related pathways
The endogenous expression levels of HOXA9 
in a panel of glioma cell lines was evaluated by qPCR 
(Supplementary Figure 1). In order to provide the first 
characterization of HOXA9 targets on a genome-wide 
level in GBM, expression microarray analyses were 
performed in matched HOXA9-positive and HOXA9-
negative human GBM cell models (U87MG-MSCV 
vs. U87MG-HOXA9, human immortalized astrocytes 
hTERT/E6/E7-MSCV vs. hTERT/E6/E7-HOXA9, U251-
shControl vs. U251-shHOXA9, and a primary GBM cell 
line GBML18-shControl vs. GBML18-shHOXA9; Figure 
2A and 2B). Due to HOXA9 expression, 3454 probes 
were significantly differentially expressed in U87MG 
cells (1537 upregulated and 1917 downregulated), 417 
probes in hTERT/E6/E7 cells (166 upregulated and 
251 downregulated), 2452 probes in U251 cells (1301 
upregulated and 1151 downregulated), and 5886 probes in 
GBML18 patient-derived primary cells (2802 upregulated 
and 3084 downregulated; Figure 2B and Supplementary 
Figures 4–9; GEO accession number GSE56517). 
Only a small subset of probes was consistently altered 
in the 3 GBM cell lines (17 probes upregulated and 40 
downregulated due to HOXA9 expression in U87MG, 
U251 and GBML18 cells), which, as expected, was even 
smaller when integrating the non-tumor immortalized 
astrocytes (1 probe upregulated and 3 downregulated; 
Figure 2B), indicating that the transcriptome of HOXA9 is 
cell-type dependent, as previously suggested in leukemia 
models [19]. Gene-specific expression analyses in a subset 
of HOXA9 targets validated the array data (Supplementary 
Figure 2A–2D).
In order to understand the biological relevance 
of the HOXA9 transcriptome, functional clustering 
annotation and integration into Kyoto Encyclo-
pedia of Genes and Genomes (KEGG), Reactome 
and Gene Ontology (GO) analyses were performed 
(Figure 2C–2F and Supplementary Figure 3A–3G). The 
HOXA9 transcriptome of non-tumoral hTERT/E6/E7 
immortalized astrocytes revealed particular enriched 
pathways in KEGG (e.g. chemokine signaling pathway 
for HOXA9-upregulated genes, and cytokine-cytokine 
receptor interaction pathway for HOXA9-downregulated 
genes; Supplementary Figure 3A). These pathways have 
been found deregulated in the context of cancer, and 
associated with increased proliferation and invasion [20]. 
In the GO integration (Figure 2C), these cells showed 
significant enrichment mainly to biological processes 
related to cellular adhesion (HOXA9-upregulated genes) 
and regulation of protein activity (HOXA9-downregulated 
genes). No significant enrichments were observed for the 
Reactome pathways in these cells. In the 3 GBM cell lines, 
the HOXA9 transcriptomes were enriched for several 
cancer-related pathways in KEGG, GO and Reactome 
analyses, including genes involved in cell cycle, DNA 
replication and repair, RNA processing, cell adhesion and 
migration, vasculature development, and immune-related 
pathways (Figure 2D–2F and Supplementary Figure 3B–
3G). Together, these data suggest the HOXA9-mediated 
genetic signatures in GBM cell models are associated 
with important cancer hallmarks that may favor tumor 
development, progression, and aggressiveness. Moreover, 
HOXA9-target genes may be important in sustaining 
the HOXA9-associated aggressive phenotype and poor 
prognosis observed in GBM patients.
We next explored the Connectivity Map tool to 
identify drugs that induce gene expression signatures 
similar to our HOXA9 transcriptome data. Interestingly, 
the top 30 gene expression signatures revealed associations 
with cancer cells treated with phosphatidylinositol 
3-kinase (PI3K) pathway inhibitors, namely LY-294002, 
sirolimus, and wortmannin (Supplementary Figure 3H), 
suggesting that our HOXA9 transcriptomic signature 
in GBM cell models is modulated by these drugs. This 
is in accordance with our previous report showing that 
inhibition of the PI3K pathway in GBM cells inhibits 
HOXA9 transcription [16], further supporting the validity 
of our microarray data. Other drug treatments that alter 
HOXA9-associated gene expression signature were found 
among the tested cell lines (Supplementary Figure 3H), 
including several anti-cancer drugs, particularly histone 
deacetylase (HDAC) inhibitors trichostatin A (TSA), 
vorinostat and MS-275 [21], which are able to promote 
cell cycle arrest and apoptosis [22], and tanespimycin and 
its analogues geldanamycin, alvespimycin, and monorden 
[23, 24], which are HSP90 inhibitors also currently tested 
as anti-cancer drugs. Together, our findings indicate 
that the HOXA9 transcriptome in GBM cells may be 
reverted by several drugs with potential anticancer effects, 
particularly those interfering with PI3K signaling, HDAC 
and HSP90 functions, which may be clinically valuable to 
revert HOXA9-driven transcriptomic signatures.
HOXA9 expression is associated with cancer 
stem cell features
HOXA9-associated transcriptional signatures 
queried with gene set enrichment analysis (GSEA) 
revealed that the HOXA9 transcriptome in hTERT/E6/E7 
cells was inversely associated with genes downregulated 
in glioma stem cells (enrichment score, ES = −0.54, false 
discovery rate, FDR = 0.19; Figure 3A), leukemia stem-
like cells, and hematopoietic stem cells (ES = −0.44, 
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Figure 2: HOXA9 transcriptomes in hTERT/E6/E7 human immortalized astrocytes, and in U87MG, U251 and 
GBML18 glioblastoma cell lines. (A) qPCR confirming the overexpression of HOXA9 in hTERT/E6/E7-HOXA9 and U87MG-
HOXA9 cells and HOXA9-silencing in U251-shHOXA9 and GBML18-shHOXA9 cells, comparing to their respective control counterparts. 
(B) Venn diagram summarizing the number of differentially expressed transcripts in the microarray data in all cell lines. The numbers in 
each area represent the total number of transcripts within each intersection. (C–F) DAVID was used to query the HOXA9-transcriptome 
from each cell line (C, hTERT/E6/E7; D, U87MG; E, U251; F, GBML18), in order to identify enriched biological terms on the differentially 
expressed genes extracted from the microarray data. Statistically significant enriched GO terms are shown for each cell line.
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Figure 3: HOXA9 transcriptomes are associated with cancer stem cell features. (A–D) GSEA reveals that the HOXA9 
transcriptomes in hTERT/E6/E7 (A) and U251 (C) cells are associated with transcriptional signatures of glioma stem-like cells (Enrichment 
Score, ES = −0.54, False Discovery Rate, FDR = 0.19; and ES = 0.50, FDR = 0.11, respectively); in U87MG cells (B), the HOXA9 
transcriptome is positively associated with genes that are upregulated in embryonic stem cells (ES = 0.50, FDR < 0.0001); in GBML18 cells 
(D), HOXA9 transcriptome is inversely associated with genes upregulated during the neuronal differentiation (ES = 0.75, FDR = 0.21). 
(E) Representative phase contrast photographs of hTERT/E6/E7 and U87MG neurospheres are shown. (F) Quantification of neurospheres 
number and size for each cell line (n = 3; *p < 0.05; ***p < 0.001). (G) Immunofluorescence showing increased Nestin staining in HOXA9-
positive cells.
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FDR = 0.21; ES = −0.45, FDR = 0.20, respectively; 
Supplementary Figure 10A and Supplementary Table 1). 
Concordantly, HOXA9 target genes in U87MG cells 
were significantly associated with genes upregulated 
in embryonic stem cells (ES = 0.50, FDR < 0.0001; 
Figure 3B), DNA repair, and cycling gene expression 
signatures (ES = 0.54, FDR < 0.0001; and ES = 0.38, 
FDR = 0.007, respectively; Supplementary Figure 10B 
and Supplementary Table 1). Similarly, the transcriptome 
of HOXA9-silenced U251 cells is significantly associated 
with genes depleted in glioma stem cells and normal 
(embryonic, neural and hematopoietic) stem cells 
(ES = 0.50, FDR = 0.11 and ES = 0.43, FDR = 0.22, 
respectively; Figure 3C, Supplementary Figure 10C and 
Supplementary Table 1); in GBML18 cell line, HOXA9-
downregulation enriched for genes upregulated during 
neuronal differentiation and in quiescent chronic myeloid 
leukemia cells (ES = 0.75, FDR = 0.21 and ES = 0.70, 
FDR = 0.21, respectively; Figure 3D, Supplementary 
Figure 10D and Supplementary Table 1). Together, 
these analyses suggest that the HOXA9-transcriptome 
is enriched for genes involved in stem-like cell features, 
a critical hallmark of cancer. To test this hypothesis, we 
evaluated the capacity of these cells to form neurospheres 
in vitro, which has been associated with stemness potential 
[25]. HOXA9 significantly increased the size and number 
of neurospheres in hTERT/E6/E7 cells as compared to 
their HOXA9-negative counterparts, which was also 
observed in a lower extent in U87MG cells (Figure 3E 
and 3F). Additionally, the expression of the neural stem 
cell marker Nestin was significantly higher in both 
hTERT/E6/E7 and U87MG HOXA9 positive cells (Figure 
3G). Together, these data suggest HOXA9 increases the 
stemness capacity of these cells.
HOXA9 expression is associated with tumor 
aggressiveness in GBM xenograft models
Considering that stem cell properties have been 
linked with tumor malignancy [14, 26, 27], together with 
our microarray data implicating the HOXA9 transcriptome 
in typical hallmarks of cancer (Supplementary Figure 3, 
Supplementary Figure 10 and Supplementary Table 1), 
we hypothesized that HOXA9 could play a role in tumor 
growth in vivo. To test this hypothesis, we established 
subcutaneous GBM xenograft models with U87MG cells. 
Tumors derived from U87MG-HOXA9 cells presented 
increased growth rates and were significantly larger than 
U87MG-MSCV cells (Figure 4A–4E). Interestingly, 
the final tumor volume was significantly correlated 
with HOXA9 expression levels (Figure 4C), further 
strengthening the relevance of HOXA9 on tumor growth 
kinetics in vivo. Histologically, HOXA9 positive tumors 
presented a higher proliferative activity, as indicated by 
increased Ki-67 staining, which includes mostly neoplastic 
cells but also non-neoplastic cells (e.g. endothelial and 
stromal cells; Figure 4F). A higher expression of Nestin 
was also observed, supporting an increased stemness 
potential of HOXA9-positive cells in vivo. Furthermore, 
the expression levels of Cyclin D1 and BCL2 were also 
increased in U87MG-HOXA9 tumors in vivo (Figure 4F). 
These proteins are critical regulators of cell cycle and cell 
death, respectively, and were identified as HOXA9 targets 
in the microarray data. Tumor-associated angiogenesis, 
another critical hallmark of GBM, as assessed by 
PECAM1 protein staining, was significantly increased in 
HOXA9-positive tumors (Figure 4F and 4G). Together, 
these data establish HOXA9 as a critical mediator of GBM 
growth and aggressiveness in vivo, and identifies critical 
molecular mediators sustaining this malignant phenotype.
HOXA9 expression contributes to glioma 
initiation and causes glioma-associated death
Given our data implicating HOXA9 as a key molecule 
in mediating several aspects of cancer aggressiveness and 
stem cell characteristics, we hypothesized that HOXA9 
may also play an important role in the tumorigenic process, 
possibly facilitating carcinogenesis initiation. To test this 
hypothesis, we evaluated the influence of HOXA9 on the 
capacity of hTERT/E6/E7 cells, a non-tumorigenic cell 
line [28], to establish tumors in vivo. In a subcutaneous 
model, hTERT/E6/E7 cells did not form tumors, regardless 
of HOXA9 expression status (Figure 5A). Considering 
the relevance of the interplay between tumor cells and 
its microenvironment, we investigated the tumorigenic 
potential of these cells in an orthotopic intracranial model. 
Strikingly, while HOXA9-negative hTERT/E6/E7 cells did 
not form tumors, the expression of HOXA9 in hTERT/E6/
E7 rendered these cells highly tumorigenic in the brain, 
accompanied by glioma-related symptomatology and 
death (Figure 5A–5E). Histological analyses of the brains 
revealed that hTERT/E6/E7-HOXA9 tumors displayed 
hallmark features of malignant gliomas, including 
pleomorphic and spindle shape tumor cells, with prominent 
nuclear polymorphism and mitotic activity, and were highly 
infiltrative throughout the meninges and brain parenchyma. 
In some cases, tumors grew outside the brain, infiltrating 
bone and soft tissues, where cells displayed a more 
sarcomatoid appearance (Figure 5D). These data clearly 
establish HOXA9 as a novel critical molecular driver in the 
initial steps of malignant transformation of brain gliomas.
HOXA9 increases GBM aggressiveness by 
affecting cell viability, death, invasion and 
resistance to temozolomide in vitro
Our data implicated HOXA9 in several hallmarks 
of cancer, including cell proliferation, invasion, 
DNA repair pathways, and cancer stem cell features 
(Figure 3, Supplementary Figure 3 and Supplementary 
Figure 10 and Supplementary Table 1). Since most of 
Oncotarget7664www.impactjournals.com/oncotarget
Figure 4: HOXA9 accelerates tumor growth in vivo. (A) U87MG cells were subcutaneously xenografted into nude mice; 
representative photographs of in vivo and ex vivo tumors are shown. (B) Longitudinal assessment of tumor volumes showing increased 
growth rates of U87MG-HOXA9 tumors as compared to HOXA9-negative tumors. (C) Positive correlation between expression levels 
of HOXA9 and tumor volume. (D) and (E) Final tumor volumes (D) and weights (E) are significantly higher in HOXA9-positive tumors 
(n = 10). (F) Hematoxilin-eosin and immunohistochemical staining showing that HOXA9-positive tumors present higher protein levels 
of Cyclin D1, Ki-67, BCL2, Nestin, and PECAM1. (G) Quantification of the % of vascular area based on PECAM1 staining, showing 
increased angiogenic potential of U87MG-HOXA9 tumors. Statistical differences were calculated by two-way ANOVA (B) and Spearman 
correlation (C), or t-tests (D and E) (*p < 0.05; **p < 0.01; ***p < 0.001).
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these characteristics have been implicated in resistance to 
treatments, we performed an integrated set of functional 
assays to investigate HOXA9’s effects on these processes, 
both in basal conditions and under temozolomide-
treatment, the gold standard chemotherapeutic agent for 
GBM patients. Both hTERT/E6/E7 and U87MG cells 
overexpressing HOXA9 presented significantly higher 
temozolomide IC50 values than their respective control cell 
lines (Figure 6A). In agreement with the overexpression 
models, we observed a decrease in temozolomide IC50 
values for both cell lines after HOXA9 downregulation 
(Figure 6B). Time-course viability assays were further 
evaluated by trypan blue exclusion (Figure 6C–6F) 
and MTS reduction (Supplementary Figure 11A–11D). 
Globally, both assays revealed that all HOXA9-high cell 
lines hTERT/E6/E7, U87MG, U251, and GBML18 (red 
lines) presented higher cell viability in basal conditions 
than their respective HOXA9-low counterparts (blue lines; 
Figure 6C–6F and Supplementary Figure 11A–11D), 
and that temozolomide-mediated cytotoxicity was 
significantly more pronounced in HOXA9-low cells than 
in HOXA9-high cells (Figure 6C–6F and Supplementary 
Figure 11A–11D), collectively indicating that HOXA9 
contributes to temozolomide resistance in GBM cells. 
We next assessed the influence of HOXA9 expression 
in cell death by annexin V staining followed by flow 
cytometry. In basal conditions, most HOXA9-high cells 
presented significantly lower levels of cell death than 
their respective HOXA9-low counterparts (Figure 6G). 
In addition, all HOXA9-high cells presented significantly 
lower levels of temozolomide-mediated cell death than 
HOXA9-low cells (Figure 6G). An important feature 
of GBM is its striking ability to invade adjacent brain 
tissue, which is a major cause of tumor recurrence and 
resistance to therapy. Using invasion assays, we observed 
that HOXA9 significantly increases the invasive capacity 
of hTERT/E6/E7, U87MG, and GBML18 cells, both in 
basal conditions and after treatment with temozolomide. In 
Figure 5: HOXA9 induces glioma initiation and tumor-associated death in intracranial orthotopic xenografts. (A) 
Nude mice were injected with HOXA9-negative and HOXA9-positive hTERT/E6/E7 immortalized astrocytes, either subcutaneously or 
intracranially. No tumor formation was observed in the subcutaneous model, regardless of HOXA9 expression. In the intracranial orthotopic 
model, HOXA9-positive hTERT/E6/E7 cells originated tumors in the majority of tested mice (70%). (B) Mice intracranially injected 
with hTERT/E6/E7-HOXA9 cells display glioma-related loss of weight. (C) Kaplan-Meier survival curves showing tumor-associated 
death exclusively in mice bearing HOXA9-positive cells (Log-rank test, p = 0.0035). (D) Histological characterization of mice brains 
orthotopically-injected with hTERT/E6/E7-control or hTERT/E6/E7-HOXA9 cells. Brains from animals injected with HOXA9-negative 
cells display a normal, non-malignant appearance (images 1 and 2 at 20x and 200x magnification, respectively), while HOXA9-positive 
cells formed tumors displaying characteristic hallmarks of malignant gliomas (images 3, 4, 5, 6 and 7 at the magnification of 20x, 40x, 
200x, 100x and 200x, respectively), including pleomorphic and spindle shape tumor cells (arrows), high mitotic activity (open arrowheads), 
prominent nuclear polymorphism (closed arrowheads), and infiltration to meninges and brain parenchyma (6 and 7). In image 4, cells 
infiltrating bone and soft tissues (#) presented a more sarcomatoid appearance, amplified in image 5. (E) RT-PCR analysis confirmed 
the expression of human GUSB housekeeping gene and HOXA9 exclusively in HOXA9-positive xenografts. Me = meninges; pa = brain 
parenchyma.
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Figure 6: Functional roles of HOXA9 in GBM cell viability, death, and invasion, under basal conditions and 
temozolomide treatment. (A and B) Determination of the half inhibitory concentration (IC50) values after 6 days of temozolomide 
(TMZ) treatment in HOXA9-positive or HOXA9-negative hTERT/E6/E7 and U87MG (A), and HOXA9-silenced or control U251 and 
GBML18 (B) cell lines. (C–F) Cell viability trypan blue assays in HOXA9-negative/low or HOXA9–positive/high hTERT/E6/E7 (C), 
U87MG (D), U251 (E) and GBML18 (F) cells, exposed to temozolomide or vehicle. (G) Cell death was evaluated by annexin V staining 
followed by flow cytometry in HOXA9-positive/high and HOXA9-negative/low hTERT/E6/E7, U87MG, U251 and GBML18 cell lines, 
both in basal conditions and after exposure to temozolomide (TMZ). HOXA9 expression decreases cell death of all GBM cell models, both 
in basal conditions and after TMZ treatment, except in basal conditions for U251 cell line. (H) Cell invasion in the same cell lines, both 
in basal conditions and after exposure to TMZ. HOXA9 increases the invasion of hTERT/E6/E7, U87MG, and GBML18 cells. U251 cells 
did not show significant differences in invasion profiles due to HOXA9 levels or TMZ treatment. Results are representative of at least three 
independent experiments, performed in triplicates (data points represent mean + SEM). Statistical differences were calculated by Student’s 
t-test (panels A, B, G, H) and two-way ANOVA (panels C–F) (*p < 0.05; **p < 0.01; ***p < 0.001).
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contrast, no significant changes in invasion were observed 
in U251 cells (Figure 6H). Since invasion and migration 
are intimately-related cellular processes, we also evaluated 
the migration capacity of U251 cells by wound healing 
assays (Supplementary Figure 12). Interestingly, U251-
shControl cells presented significantly higher migration 
rates than U251-shHOXA9 counterparts. Together, our 
data consistently establishes the functional relevance of 
HOXA9 expression in several hallmarks of GBM cells 
behavior, by affecting key cellular processes such as 
cell viability, death, invasion, and drug resistance, which 
together may dictate the more aggressive behavior and 
poorer clinical outcome of HOXA9-positive GBMs.
HOXA9 expression associates with 
shorter survival and increased resistance 
to temozolomide in orthotopic GBM 
xenograft models
In order to validate the prognostic value of HOXA9 
observed in GBM patients (Figure 1E–1G, and [16]), 
and its relevance in temozolomide chemo-resistance 
observed in vitro (Figure 6 and Supplementary Figure 11), 
we established intracranial orthotopic GBM xenografts 
with U87MG-MSCV and U87MG-HOXA9 cells in nude 
mice (Figure 7A). Untreated animals bearing U87MG-
HOXA9-derived tumors presented significantly lower 
overall survival (median 28 days) than their respective 
negative counterparts (median 46 days; Log rank test, 
p = 0.0001; Figure 7A). Additionally, while treatment 
with temozolomide was able to significantly extend 
overall survival of all animals (median OS increased from 
46 to 140 days in mice bearing U87MG-MSCV tumors, 
p < 0.0001; and median OS from 28 to 65 days in mice 
bearing U87MG-HOXA9 tumors, p = 0.0002; Figure 7A), 
those bearing HOXA9-expressing tumors presented a 
significantly shorter overall survival than animals bearing 
HOXA9-negative tumors (p < 0.0001; Figure 7A). 
Histological and RT-PCR analyses confirmed tumor 
formation and HOXA9 expression levels in tumors excised 
from mice brains (Figure 7B and 7C, respectively). Taken 
together, our in vivo experiments specifically establish 
HOXA9 as a solid biomarker of prognosis in GBM and its 
relevance in determining temozolomide chemo-resistance.
HOXA9 affects important pathways involved in 
temozolomide response
The most well established mechanisms of 
temozolomide resistance include MGMT, base-excision 
repair (BER), and mismatch-repair (MMR) proteins 
[29]. In order to understand the mechanisms by which 
HOXA9 may affect drug resistance and mice survival, 
we investigated if HOXA9 affects these key pathways. 
By using methylation-specific PCR, we observed that 
U87MG cells presented a methylated MGMT promoter, 
independently of HOXA9 expression (Supplementary 
Figure 13A). Concordantly, no differences in MGMT 
mRNA expression and protein levels were detected 
(Supplementary Figure 13B and 13C). Thus, the HOXA9-
mediated temozolomide resistance in U87MG cells is not 
likely mediated by MGMT. Similarly, the levels of BER 
proteins (PCNA, PARP1, APEX1, and XRCC1) were not 
significantly affected by HOXA9 (Supplementary Figure 
13D). In contrast, the expression of some key proteins 
of the MMR pathway, including PMS2 and MSH6, was 
significantly decreased due to HOXA9 (Figure 7D). Since 
a functional MMR pathway is crucial for temozolomide 
sensitivity by inducing apoptosis after DNA damage, the 
down-regulation of these key MMR proteins in HOXA9-
positive U87MG cells may be an additional mechanism of 
temozolomide resistance.
Critically, it is not straightforward to therapeutically 
intervene at proteins of the MMR pathway in the clinical 
setting. Thus, we revisited our microarray data to identify 
other putative mechanisms of drug resistance. Interestingly, 
we identified several genes involved in apoptosis and drug 
response that were differentially expressed in U87MG-
HOXA9 cells (e.g., upregulation of anti-apoptotic BCL2, 
TRAIP, BAG1, BAG5, API5, SET; and downregulation of 
pro-apoptotic NLRP1, BLID, APLP1, ADCK3). Of these, 
BCL2 was particularly interesting because it was one of 
the top 50 most significantly up-regulated genes in our 
HOXA9 array data (Supplementary Figure 5). BCL2 is a 
critical anti-apoptotic protein involved in resistance to DNA 
damaging agents in many cancer types [30], for which 
pharmacological inhibitors are available, some of which 
have shown promising results in the treatment of solid 
tumors [31, 32]. Thus, we investigated how HOXA9 may 
affect temozolomide response via BCL2. We first confirmed 
that BCL2 is significantly overexpressed at the mRNA 
and protein levels in HOXA9-positive cells (Figure 7E 
and 7F), which was consistent with increased levels 
of BCL2 protein in HOXA9-expressing subcutaneous 
tumor (Figure 4F). In order to confirm the link between 
HOXA9-mediated BCL2 overexpression and resistance 
to temozolomide, and to explore novel combinatorial 
treatments to GBM, we evaluated how ABT-737, a potent 
small molecular inhibitor of BCL2 family proteins, affects 
the response of U87MG cells to temozolomide. While 
no significant cytotoxic effects were observed for two 
different doses of ABT-737 alone (0.25 and 5 μM), the 
combination of ABT-737 with temozolomide significantly 
increased cytotoxicity of U87MG cells, an effect that 
was significantly more pronounced in HOXA9-positive 
cells (Figure 7G). This finding supports the evidence that 
BCL2 could be associated with temozolomide resistance 
in U87MG HOXA9-positive cells. Importantly, the use 
of this BCL2 inhibitor together with temozolomide did 
not affect cytotoxicity of cells lacking BCL2 expression 
(Supplementary Figure 14A and 14B), which supports 
the specificity of the observed effect. Importantly, in the 
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Figure 7: HOXA9 decreases overall survival and increases resistance to temozolomide in vivo via mismatch-repair 
and BCL2 proteins. (A) Kaplan-Meier survival curves for in vivo orthotopic intracranial GBM models. While temozolomide (TMZ) 
treatment successfully increased overall survival, HOXA9-positive tumors cause significantly decreased overall survival in both untreated 
and TMZ-treated animals (Log-rank test HOXA9 vs MSCV, p = 0.0001; HOXA9 TMZ vs MSCV TMZ, p < 0.0001). (B) Hematoxylin-
eosin staining of mice brains showing a well-delimited tumor area (T  ) with GBM-like features, and surrounding non-tumor brain tissue (N).  
(C) RT-PCR analysis confirmed the expression of HOXA9 in brain tumors derived from U87MG-HOXA9-xenografted cells. (D) Western Blot 
to mismatch-repair proteins (MMR), showing that HOXA9 decreases the expression of PMS2 and MSH6 proteins in U87MG cells in vitro. 
(E) and (F) qPCR and Western blot analyses of BCL2 mRNA and protein levels, respectively, showing HOXA9 significantly increases 
BCL2 levels. Results are representative of three independent experiments for each blot. (G) Cell viability of U87MG HOXA9-negative or 
-positive cells after 4 days of treatment with vehicle, Temozolomide (TMZ), ABT-737 (BCL2 inhibitor), or both. HOXA9-positive cells 
are significantly more sensitive to the combination of TMZ and ABT-737 than HOXA9-negative cells. Results are representative of three 
independent experiments, performed in triplicates (data points represent mean + standard deviation). Statistical differences calculated by 
Student t-tests (*p < 0.05; **p < 0.01; ***p < 0.001).
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TCGA dataset, 87% of the HOXA9-high GBM patients 
also display high levels of BCL2, emphasizing that the 
link between HOXA9 and BCL2 is not only present in in 
vitro and in vivo models of GBM, but is also relevant in the 
clinical setting. These data supports the future exploitation 
of BCL2 inhibitors combined with temozolomide for the 
treatment of GBM patients.
DISCUSSION
Previous studies have shown that HOX genes are 
part of large gene expression signatures that associate with 
glioblastoma self-renewal and therapy response [12–14]. 
However, the specific contribution of individual HOX genes 
in glioblastoma behavior has been largely unknown. In 
particular, HOXA10 expression was recently shown to be 
regulated by the Trithorax protein mixed lineage leukemia 
(MLL), resulting in the activation of HOXA10-target genes 
that contribute to the tumorigenic potential of glioblastoma 
stem cells [14]. Another study suggested HOXA10 may 
contribute to temozolomide resistance in vitro [15]. While 
HOXA9 was also previously shown to display pro-viability 
and anti-apoptotic functions in glioblastoma in vitro [16], the 
downstream functional consequences of HOXA9 activation 
have remained unknown. Here, we specifically investigated 
for the first time the genome-wide transcriptional targets 
of HOXA9 in four independent GBM cell models, and 
evaluated how HOXA9 affects critical cellular and 
molecular processes of the malignant phenotype of gliomas, 
using a combination of in vitro and in vivo models.
Interestingly, our expression array data showed 
an HOXA9-mediated enrichment of genes involved 
in several important hallmarks of cancer (Figure 2 
and Supplementary Figure 3). The fact that HOXA9 
transcriptomes were so distinct within GBM cells 
(U87MG, U251 and GBML18) and in immortalized 
astrocytes (hTERT/E6/E7) cells suggests that HOXA9 
targets different genes in a cell-type dependent manner, 
which is in accordance with previous reports in leukemia 
models [19]. Despite these specificities, GSEA analysis 
revealed that HOXA9 transcriptomes are enriched for 
genes involved in stem cell signatures, which fits well 
with the previously reported HOX-dominated gene 
expression signatures found in glioblastoma stem 
cells [12–14, 19], and suggests HOXA9 as a critical 
component of that signature. Concordantly, the single 
overexpression of HOXA9 increased the capacity of 
these cells to grow as neurospheres and upregulated the 
expression of Nestin (Figure 3), both of which have been 
related to the stemness potential of GBM cells [25]. Our 
data in GBM also identified novel HOXA9 target genes 
involved in cell proliferation and cytoskeletal organization 
pathways, which have previously been identified as 
HOXA9 downstream effectors in leukemia [19]. Genes 
involved in other critical pathways, including DNA 
repair, cell invasion, cell mobility and immune response, 
were also found up-regulated due to HOXA9 (Figure 2, 
Supplementary Figure 3 and Supplementary Figure 10). 
Together, our findings suggest that several molecular 
pathways act downstream of HOXA9 to maintain a 
malignant phenotype in GBM. Critically, these HOXA9-
driven signatures may be pharmacological reverted 
by PI3K inhibitors and chromatin-remodeling drugs, 
as suggested previously [13, 16, 33] and now by our 
connectivity map analyses (Supplementary Figure 3H).
The importance of the cancer stem cell population in 
tumor initiation, progression, and response to therapy has 
been well documented [34]. Consistent with the increased 
stem cell features displayed by HOXA9-positive cells, our 
subcutaneous xenograft models using U87MG cells showed 
that HOXA9 accelerates tumor growth and tumor-related 
angiogenesis, with a concomitant increase in the expression 
of proteins involved in these cellular processes (Cyclin 
D1, Ki-67, BCL2, and PECAM1; Figure 4). Strikingly, we 
also showed that hTERT/E6/E7 immortalized astrocytes 
that overexpress HOXA9 are able to originate orthotopic 
gliomas in vivo, in contrast to HOXA9-negative hTERT/
E6/E7 cells (Figure 5), which may partly be explained by 
the notion that tumor-initiating cells have high stem cell 
potential. While HOXA9 is an established oncogene in the 
context of leukemia [35, 36], our study is the first to clearly 
demonstrate the oncogenic potential of HOXA9 in gliomas.
Previous studies have provided circumstantial 
evidence suggesting HOX genes may be important in 
the aggressiveness of GBM [11–13, 16]. However, the 
functional mechanisms by which particular HOX genes 
may contribute to this malignant phenotype have not 
been elucidated. In the present study, we employed both 
overexpression and shRNA-mediated silencing approaches 
to investigate the functional roles of HOXA9 in four 
independent GBM models. Globally, our data show that 
HOXA9 increases cell viability, invasion, and resistance 
to cell death in GBM (Figure 6 and Supplementary Figure 
11), establishing a good parallel with HOXA9 functions 
observed in leukemia models [37, 38]. In addition, 
HOXA9 significantly increased the resistance of all tested 
GBM cell lines to temozolomide treatment (Figure 6  
and Supplementary Figure 11), establishing HOXA9 as 
a new biomarker of temozolomide response in GBM. Of 
note, this HOXA9-driven resistance to temozolomide 
is likely to be independent of p53 function, as the cell 
lines tested here have different p53 status ( p53 wild-
type in U87MG; p53 mutant in U251; p53 inactivated 
in hTERT/E6/E7). Critically, the increased resistance 
to temozolomide mediated by HOXA9 was validated 
in vivo, as U87MG-HOXA9-xenografted animals 
presented a significantly shorter survival than those 
xenografted with U87MG-MSCV cells (Figure 7). In 
order to provide further insights into the mechanisms of 
HOXA9-mediated resistance to chemotherapy, which are 
critical to help designing novel therapeutic strategies to 
treat GBM patients, we investigated canonical markers 
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of temozolomide response in GBM. Interestingly, 
HOXA9 did not affect the protein levels of MGMT, or 
the DNA methylation status of the MGMT promoter, 
which is a major regulator of temozolomide response. 
In contrast, HOXA9 affected the expression of other key 
proteins involved in temozolomide response, including 
down-regulation of MMR family proteins PMS2 and 
MSH6 (Figure 7). MMR deficiency has been implicated 
in preclinical studies as an additional mechanism of 
resistance to alkylating agents, including temozolomide 
[39]. Specifically, reduction of PMS2 protein levels was 
found to be associated with temozolomide resistance, 
and inactivating mutations of MSH6 gene and loss of 
MSH6 function have been associated with emergent 
temozolomide resistance in GBM patients [40, 41]. Our 
data suggest a novel HOXA9-driven mechanism of MMR 
deficiency in GBM that may decrease the therapeutic 
value of temozolomide. Since reestablishing MMR 
protein levels/function is not clinically feasible, we 
explored additional mechanisms by which HOXA9 may 
drive temozolomide resistance in GBM. Interestingly, 
we found that HOXA9 increases the expression of 
the anti-apoptotic protein BCL2 in vitro and in vivo 
(microarray, qPCR, immunohistochemistry and Western 
blot data). Importantly, the majority of GBM patients 
with HOXA9-high tumors also display high levels of 
BCL2 (TCGA data), indicating that this molecular link 
is clinically relevant and not only exclusive of GBM 
models. Indeed, BCL2 was recently shown to be a target 
of HOXA9 in acute myeloid leukemia [42]. BCL2 
has been considered an attractive target for anticancer 
therapies as it can be pharmacologically inhibited and, 
thus, potentiate apoptosis in cancer cells [30–32]. Indeed, 
the blockade of BCL2 activity has shown promising 
results in several cancers, such as pediatric lymphoblastic 
leukemia [43], neuroblastoma [44], melanoma [45], 
genitourinary neoplasm [30], and glioblastoma [46]. A 
recent study showed that the down-regulation of BCL2 
restored temozolomide sensitization in a GBM cell line 
[47]. Another study showed a positive effect of ABT-
737, a BCL2 inhibitor, in restoring chemosensitivity 
to vincristine and etoposide [46]. These data prompted 
us to evaluate how inhibition of BCL2 function could 
sensitize HOXA9-positive GBM cells to temozolomide. 
Interestingly, a combination of temozolomide and 
ABT-737 had a significant increased cytotoxic effect as 
compared to temozolomide alone, exclusively in U87MG-
HOXA9 cells (Figure 7). Of note, a similar combination 
of temozolomide and ABT-737 did not affect the viability 
of BCL2-negative cells, providing a proof-of-concept that 
the HOXA9-mediated resistance to temozolomide can be 
partly reverted by specifically inhibiting BCL2 function. 
Of note, ABT-737 may be too large to cross the blood-
brain barrier, which could limit its clinical application. 
Nevertheless, malignant gliomas frequently present a 
focal breach of the BBB caused by a loss of tight junctions 
[48], allowing blood-borne molecules to enter the brain 
parenchyma. On other hand, the intracranial delivery 
of ABT-737 might be possible in the future through the 
use of nanoparticle-based delivery systems, through 
intraventricular administration, or by using implantable 
wafers. Future studies should further investigate how these 
combinatory treatments can be more effective to treat the 
subset of GBM patients with high levels of HOXA9/
BCL2, helping to improve the outcome of these highly 
therapy resistant tumors.
In conclusion, our study establishes HOXA9 as 
a critical oncogene in the initiation and progression of 
glioma, and provides evidences into the mechanisms by 
which patients with HOXA9-positive GBMs respond 
poorly to temozolomide and have worse clinical outcomes. 
These findings may have clinical impact by allowing the 
timely identification of patients that may not benefit from 
temozolomide-based treatment, who could be redirected to 
alternative therapeutic regimens, namely based on BCL2 
inhibition.
MATERIALS AND METHODS
Detailed methodologies are described in 
Supplementary Data.
TCGA and REMBRANDT meta-analysis in 
glioma patients
Gene expression, copy number, DNA methylation, 
MGMT promoter methylation, GBM subtype 
classification, and clinical data from GBM, lower-grade 
glioma (LGG, WHO grades II and III), and normal 
samples were collected from TCGA (http://tcga-data.nci.
nih.gov/). HOXA9 expression and prognostic value was 
also assessed in patients from REMBRANDT (https://
caintegrator.nci.nih.gov/rembrandt/).
Cell lines
Four different GBM cell line models were used: 
two established human GBM cell lines (U87MG and 
U251), immortalized human astrocytes (hTERT/E6/
E7), and a primary GBM culture (GBML18) established 
in our lab as previously described [49]. All cell lines 
were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% 
penicillin-streptomycin and incubated at 37ºC in 5% 
CO2. The commercial cell lines U87MG and U251 were 
authenticated by short tandem repeat profiling.
HOXA9-overexpression and silencing in 
GBM cells
U87MG and hTERT/E6/E7 were previously 
retrovirally infected with MSCVneo vectors containing 
HOXA9 cDNA [16]. For HOXA9 silencing, GBML18 and 
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U251 cells were transfected with pGFP-V-RS plasmid 
containing HOXA9-specific shRNAs or non-effective 
shRNAs sequences (Origene).
Gene expression microarray analyses
Genome-wide transcriptome profiles of U87MG 
and hTERT/E6/E7 cells with MSCV (control) or 
HOXA9 vectors, and U251 and GBML18 with pGFP-
V-RS plasmid containing HOXA9-specific shRNAs or 
non-effective shRNAs sequences were performed by 
expression microarrays (Whole Human Genome 44k Oligo 
Microarray Kit, Agilent) and validated by RT-PCR or 
quantitative real-time PCR. Microarray data and full details 
on the experimental procedures are published online at 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=ebmfagkwxrkndqx&acc; GEO 
accession number GSE56517).
Differentially-expressed genes were used for 
Database for Annotation, Visualization and Integrated 
Discovery (DAVID) analyses and displayed in KEGG, 
GO, or Reactome pathways. For gene set enrichment 
analysis (GSEA; http://www.broad.mit.edu/gsea/), 
databases from MSigDB C2 collection version three 
were used, and results with false discovery rate (FDR) 
< 0.25 were considered significant [50]. Connectivity 
Map was used to verify the similarity between HOXA9 
transcriptome in GBM models with drug treatments-
induced gene expression signatures in cancer models [51].
Functional assays
Neurospheres formation assay was performed 
in hTERT/E6/E7 and U87MG cell lines. For all cell 
lines the half maximal inhibitory concentration (IC50) 
of temozolomide (TMZ) was determined by MTS 
(Promega), following the manufacturer´s instructions. 
Time-course cell viability assays were determined by 
Trypan blue exclusion assays (Gibco®) and MTS tests. 
Cell death was evaluated by annexin V staining (BD 
Biosciences), followed by flow cytometry analyses. 
Invasion was measured using the BD BioCoat™ Tumor 
Invasion System (BD Biosciences) as indicated by the 
manufacturer’s instructions.
Immunohistochemistry, immunofluorescence 
and western blot
Immunohistochemistry or immunofluorescence 
staining was conducted using antibodies against Cyclin 
D1, Ki-67, BCL2, Nestin and PECAM1. Tumor vascular 
area was calculated as the percentage of PECAM1 positive 
cells in at least 17 consecutive areas (100x: ~0.63 mm2) 
evaluated per tumor. Western blot was performed using 
antibodies against MGMT, BCL2, MSH3, MSH2, PMS2, 
MSH6, MLH3, MLH1, PCNA, PARP1, APEX1, XRCC1. 
All antibodies are listed in Supplementary Table 2.
RT-PCR and quantitative real-time PCR
RNA extraction was performed by TRIzol 
(Invitrogen) and cDNA synthetized using RT-Phusion 
Kit, Thermo Scientific. Gene-specific mRNA levels were 
assessed by standard RT-PCR or quantitative PCR (qPCR), 
using the ΔΔCt method as described previously [52]. All 
primers sequences are listed in Supplementary Table 3.
DNA isolation, bisulfite treatment and MGMT 
methylation-specific PCR
DNA was isolated from cell lines using TRIzol 
(Invitrogen) and treated with sodium bisulfite using the 
EZ DNA Methylation-GoldTM Kit (Zymo Research), 
according to the manufacturer’s protocol. Methylation-
specific PCR for MGMT promoter was performed as 
previously described [53].
In vivo GBM xenografts
All experiments with mice were approved by 
institutional and national ethical committees (Direção 
Geral de Alimentação e Veterinária, Portugal) and in 
accordance with European Union Directive 2010/63/
EU. Subcutaneous and orthotopic xenograft models were 
performed by injecting U87MG and hTERT/E6/E7 cells 
with or without HOXA9.
Statistical analyses
SPSS 19.0 software (SPSS, Inc.), GraphPad Prism 
software (version 5.0) and the Bioconductor platform 
were used. Statistical significance was considered when 
p < 0.05.
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